Ankylosing spondylitis (AS) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051102

AS restriction and item codes

Do not share this attachment externally. See Freedom of Information - Information Publication Scheme.

$\\INTERNAL.DEPT.LOCAL\Shared\NAT\SERDELEXCEL\WORKPRODIMP\Operation Blueprint Migration\RDT Release Icons\32w\icon-hidden-attachment.png$ PBS AS restriction and item codes

Calculator

Next assessment date (NAD) calculator

Contact details

PBS Complex Drugs Programs

Forms

Ankylosing spondylitis - initial authority application (PB073)

Ankylosing spondylitis - continuing authority application (PB074)

Ankylosing spondylitis - change, recommencement or demonstration of response authority application (PB251)

Ankylosing spondylitis - bimekizumab - initial grandfather authority application (PB352)

Services Australia website

Ankylosing spondylitis

External websites

PBS schedule for ankylosing spondylitis

FAQs from Service Officers

Table 1: see the Table 2 in Processing Complex Authority Required Listings for FAQs relevant to all Complex programs.

Item	Description
1	Does the first continuing have to be after 12 weeks? Yes, the patient needs to have at least 12 weeks of treatment to demonstrate a response to treatment. Measure 12 weeks from approval. Note: the date of test results cannot be greater than 4 weeks from the end of the most recent course of treatment.
2	The prescriber did not provide the patient’s ESR at baseline but the patient is meeting ESR now. Is this ok? No, a response can only be against the parameters provided at baseline.
3	The prescriber provided the patient’s ESR and CRP at baseline but the patient is only meeting CRP currently. Is this ok? Yes. As long as both bloods were qualifying for entry at baseline, only responding on one of them currently is ok.

Operational Information